Clovis Oncology


Download Documentation Clovis Oncology, Inc. at the 36th Annual JP Morgan Conference Presentation
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 3.6 (6.10%)
Intraday High$60.04
Intraday Low$54.25
Data as of 01/16/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
01/04/18Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast of the presentation and breakout session can be accessed throu... 
Printer Friendly VersionDownload PDF
12/19/17Rucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018
Treatment indication remains under active review The Scientific Advisory Group advice will assist CHMP to reach a positive or negative opinion In January 2018, the Company plans to notify the EMA of its intent to submit a new MAA in Q2 2018 for the maintenance treatment indication in women with advanced ovarian cancer In the event of a positive CHMP opinion and corresponding EMA approva... 
Printer Friendly VersionDownload PDF
12/05/17Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
Clovis seeks U.S. approval for rucaparib as maintenance therapy for women with recurrent ovarian cancer who are platinum sensitive, and in complete or partial response to platinum chemotherapy, with no requirement for diagnostic testing Priority review granted based on positive data from phase 3 ARIEL3 clinical trial in which rucaparib significantly improved PFS in all ovarian cancer patient populations studied ... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.